Tozadenant (Parkinson’s Disease) - Forecast and Market Analysis to 2022

GlobalData
March 31, 2014
85 Pages - GLDATA18033
$3,495.00

Summary

Parkinson’s disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability. As the second most common neurodegenerative disorder, Parkinson’s disease may affect individuals of any age but prevalence is increased with age and it is most common in the elderly. Dopaminergic therapies have been fairly effective in treating bradykinesia, but several unmet needs remain. Some needs will be met during the forecast period from 2012-2022, while others, such as the need for disease-modifying drugs, will remain. GlobalData expects that advancements will be made in levodopa administration and that four new molecular entities will be introduced to the market by 2022, these factors along with increased patient numbers from an aging population will drive the market during the forecast period.

Tozadenant is an adenosine 2A inhibitor in Phase IIb/III of development by Biotie. The compound was originally developed by Roche and subsequently licensed to Synosia, where it was further developed under the development code SYN115. License ownership was transferred to Biotie following a merger with Synosia in January 2011. UCB and Biotie entered into a marketing partnership in 2010 for the development and commercialization of tozadenant.

Scope

- Overview of Parkinson’s disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Tozadenant including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Tozadenant for the top six countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain and the UK.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Parkinson’s disease
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Tozadenant performance
- Obtain sales forecast for Tozadenant from 2012-2022 in the top six countries (the US, France, Germany, Italy, Spain and the UK).

'

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 9
2 Introduction 10
2.1 Catalyst 10
2.2 Related Reports 10
3 Disease Overview 13
3.1 Etiology and Pathophysiology 13
3.1.1 Etiology 13
3.1.2 Pathophysiology 16
3.1.3 Prognosis 18
3.1.4 Quality of Life 19
3.2 Symptoms 19
4 Disease Management 21
4.1 Overview 21
4.1.1 Diagnosis - The UK Brain Bank Criteria 21
4.1.2 Treatment Guidelines and Leading Prescribed Drugs 22
4.2 Treatment Synopsis 25
4.2.1 Dopaminergic Therapy Classes 25
4.2.2 Treatment of Parkinson’s Disease by Stage 27
4.2.3 Other Treatment Options 30
4.3 Parkinson’s Disease Assessment Scales 30
4.3.1 Unified Parkinson’s Disease Rating Scale (UPDRS) 31
4.3.2 Hoehn and Yahr Clinical Staging 33
4.3.3 Other Clinical Assessments 34
5 Competitive Assessment 35
5.1 Overview 35
5.2 Strategic Competitor Assessment 37
6 Opportunity and Unmet Need 38
6.1 Overview 38
6.2 Treatment of Motor Complications - Dyskinesias and OFF Episodes 40
6.2.1 Unmet Need 40
6.2.2 Gap Analysis 42
6.2.3 Opportunity 45
6.3 Treatment of Non-Motor Symptoms and Dementia 45
6.3.1 Unmet Need 45
6.3.2 Gap Analysis 46
6.3.3 Opportunity 48
6.4 Neuroprotective/Disease-Modifying Agents 48
6.4.1 Unmet Need 48
6.4.2 Gap Analysis 49
6.4.3 Opportunity 52
6.5 Improved Drug Formulations 53
6.5.1 Unmet Need 53
6.5.2 Gap Analysis 53
6.5.3 Opportunity 54
6.6 Identification of Reliable Biomarkers 54
6.6.1 Unmet Need 54
6.6.2 Gap Analysis 55
6.6.3 Opportunity 56
6.7 Improved Clinical Trial Design 56
6.7.1 Unmet Need 56
6.7.2 Gap Analysis 57
6.7.3 Opportunity 57
7 Pipeline Assessment 58
7.1 Overview 58
7.2 Promising Drugs in Clinical Development 58
8 Tozadenant 61
8.1 Overview 61
8.2 Efficacy 62
8.3 Safety 63
8.4 Dosing and Formulation 63
8.5 Potential Clinical Positioning 63
8.6 Potential Commercial Positioning 63
8.7 Pricing and Reimbursement 64
8.8 SWOT Analysis 64
8.9 Forecast 64
9 Appendix 66
9.1 Bibliography 66
9.2 Abbreviations 72
9.3 Methodology 76
9.4 Forecasting Methodology 76
9.4.1 Diagnosed Parkinson’s Disease Patients 76
9.4.2 Percent Drug-Treated Patients 77
9.4.3 General Pricing Assumptions 77
9.4.4 Compliance Assumptions 78
9.4.5 Individual Drug Assumptions 78
9.4.6 Generic Erosion 79
9.4.7 Pricing of Pipeline Agent 79
9.5 Physicians and Specialists Included in this Study 80
9.6 About the Authors 82
9.6.1 Author 82
9.6.2 Global Head of Healthcare 83
9.7 About GlobalData 84
9.8 Disclaimer 84

1.1 List of Tables
Table 1: Symptoms of Parkinson’s Disease 20
Table 2: UK Brain Bank Diagnostic Criteria 22
Table 3: Diagnosis and Treatment Guidelines for Parkinson’s Disease 23
Table 4: Most Prescribed Drugs for Parkinson’s Disease by Class in the Global Markets, 2014 24
Table 5: Dopaminergic Therapy in Parkinson’s Disease 27
Table 6: UPDRS Clinical Assessment of Disease Severity 32
Table 7: Parkinson’s Disease Assessment Scales Used in Clinical Trials 34
Table 8: Treatment of Motor Symptoms in Parkinson’s Disease 36
Table 9: Leading Treatments for Parkinson’s Disease, 2014 37
Table 10: Unmet Need and Opportunity in Parkinson’s Disease 39
Table 11: Dyskinesia Pipeline, 2014 44
Table 12: Dementia Pipeline, 2014 47
Table 13: Parkinson’s Disease-Modifying Therapeutics Pipeline, 2014 51
Table 14: Product Profile - Tozadenant 62
Table 15: Tozadenant SWOT Analysis, 2014 64
Table 16: Global Sales Forecasts ($m) for Tozadenant, 2012-2022 65

1.2 List of Figures
Figure 1: Overview - L-dopa Metabolism and Inhibitor Classes 26
Figure 2: Overview - Treatment of Motor Symptoms of Parkinson’s Disease 28
Figure 3: Pharmacokinetics of Levodopa 41
Figure 4: Parkinson’s Disease - Phase II-III Pipeline, Segmented by Indication, 2014 59
Figure 5: Competitive Assessment of Late-Stage Pipeline Agents in Parkinson’s Disease, 2012-2022 60

$3,495.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Custom Research

Need a custom report
tailored to your goals and budget? 

E-mail us your project outline
or call Client Services to speak
with your industry analyst.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Discount Codes

Request Discount Codes
for reports of interest to you.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax